Anticoagulant initiation after cardioembolic stroke: practical timing and options
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20252872Keywords:
Timing, Atrial fibrillation, StrokeAbstract
Cardioembolic Stroke (CES) is a leading cause of Acute Ischemic Stroke (AIS) and is linked to worse outcomes. There is a notably increased risk of “hemorrhagic transformation” (HT) in CES cases, where anticoagulant therapy is essential for patients with atrial fibrillation (AF) to prevent future strokes. Additionally, larger infarcts are associated with a higher risk of HT, effectively doubling the mortality risk. Currently, there are no clear guidelines connecting infarct size to “anticoagulation” decisions or management of HT cases. This review specifically focuses on the timing of “anticoagulation” initiation in patients with AF. Out of 380 articles evaluated, 50 relevant studies were included in this review. Generally, existing guidelines recommend starting “anticoagulation” between 4 to 14 days after anAIS. The review seeks to summarize current research on early versus late “anticoagulation” initiation in AF patients who experience AIS, providing clinicians with practical insights on optimal timing and the selection of effective and safe anticoagulants.
Metrics
References
Hart RG, Diener HC, Coutts SB, Easton JD, Granger CB, O’Donnell MJ, et al. Cryptogenic Stroke/ESUS International Working Group. Embolic strokes of undetermined source: The case for a new clinical construct. Lancet Neurol. 2014;13:429–38. DOI: https://doi.org/10.1016/S1474-4422(13)70310-7
Liu C, Shi F, Chen Z, Yan S, Ding X, Lou M. Severe blood-brain barrier disruption in cardioembolic stroke. Front Neurol. 2018;9:55. DOI: https://doi.org/10.3389/fneur.2018.00055
Aguilar MI, Hart R, Pearce LA. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonvalvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2007;3:6186. DOI: https://doi.org/10.1002/14651858.CD006186.pub2
Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2019;50:344-418. DOI: https://doi.org/10.1161/STR.0000000000000211
Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardio thorac Surg. 2016;50:1-88. DOI: https://doi.org/10.1016/j.rec.2016.11.033
Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II). Lancet. 1998;352:1245-51. DOI: https://doi.org/10.1016/S0140-6736(98)08020-9
Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-29. DOI: https://doi.org/10.1056/NEJMoa0804656
Kobayashi, S. (Ed.) Stroke Data Bank 2015; Nakayama Shoten: Tokyo, Japan. 2015.
Caplan LR, Gorelick PB, Hier DB. Race, sex and occlusive cerebrovascular disease: A review. Stroke. 1986;17:648–55. DOI: https://doi.org/10.1161/01.STR.17.4.648
Minematsu K, Yamaguchi T, Omae T. ‘Spectacular shrinking deficit’: Rapid recovery from a major hemispheric syndrome by migration of an embolus. Neurology. 1992;42:157–62. DOI: https://doi.org/10.1212/WNL.42.1.157
Sussman ES, Connolly ES. Hemorrhagic transformation: A review of the rate of hemorrhage in the major clinical trials of acute ischemic stroke. Front. Neurol. 2013;4:69. DOI: https://doi.org/10.3389/fneur.2013.00069
Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, et al. ASSERT Investigators. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012;366(2):120-9. DOI: https://doi.org/10.1056/NEJMoa1105575
January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, et al. ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):199-267. DOI: https://doi.org/10.1161/CIR.0000000000000041
Singh RJ, Chakraborty D, Dey S, Ganesh A, Al Sultan AS, EesaM, et al. Intraluminal thrombi in the cervico-cephalic arteries. Stroke. 2019;50:357-64. DOI: https://doi.org/10.1161/STROKEAHA.118.023015
Das S, Goldstein ED, de Havenon A, Abbasi M, Nguyen TN, Aguiar de Sousa D, et al. Composition, treatment, and outcomes by radiologically defined thrombus characteristics in acute ischemic stroke. Stroke. 2023;54:1685-94. DOI: https://doi.org/10.1161/STROKEAHA.122.038563
Saxena R, Lewis S, Berge E, Sandercock PA, Koudstaal PJ. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the international stroke trial. Stroke. 2001;32:2333-7. DOI: https://doi.org/10.1161/hs1001.097093
Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, et al. Thirty-day mortality after ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation on and off anticoagulants. Stroke. 2012;43:1795-9. DOI: https://doi.org/10.1161/STROKEAHA.111.630731
Paciaroni M, Agnelli G, CoreaF, Ageno W, Alberti A, Lanari A, et al. Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study. Stroke. 2008;39:2249-56.
Van der Steen W, van der Ende NA, van Kranendonk KR, Chalos V, Brouwer J, van Oostenbrugge RJ, et al. Timing of symptomatic intracranial hemorrhage after endovascular stroke treatment. Eur Stroke J. 2022;7:393-401. DOI: https://doi.org/10.1177/23969873221112279
Paciaroni M, Agnelli G, Caso V, Tsivgoulis G, Furie KL, Tadi P, et al. Prediction of early recurrent thromboembolic event and major bleeding in patients with acute stroke and atrial fibrillation by a risk stratification schema: the ALESSA score study. Stroke 2017;48:726-732. DOI: https://doi.org/10.1161/str.48.suppl_1.tmp91
Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263-72. DOI: https://doi.org/10.1378/chest.09-1584
Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093-100. DOI: https://doi.org/10.1378/chest.10-0134
Kidwell CS, Saver JL, Carneado J, Sayre J, Starkman S, Duckwiler G, et al. Predictors of hemorrhagic transformation in patients receiving intra-arterial thrombolysis. Stroke. 2002;33(3):717-24. DOI: https://doi.org/10.1161/hs0302.104110
Mason PK, Lake DE, DiMarco JP, Ferguson JD, Mangrum JM, Bilchick K, et al. Impact of the CHA2DS2-VASc score on “anticoagulation” recommendations for atrial fibrillation. Am J Med. 2012;125:61–6. DOI: https://doi.org/10.1016/j.amjmed.2011.09.030
Ahmed N, Steiner T, Caso V, Wahlgren N; ESO-KSU Session Participants. Recommendations from the ESO-Karolinska Stroke Update Conference, Stockholm 13-15 November 2016. Eur Stroke J. 2017;2:95-102. DOI: https://doi.org/10.1177/2396987317699144
Paciaroni M, Agnelli G, Falocci N, Caso V, Becattini C, Marcheselli S, et al. Early recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation: effect of “anticoagulation” and its timing: The RAF Study. Stroke. 2015;46(8):2175-82. DOI: https://doi.org/10.1161/STROKEAHA.115.008891
Paciaroni M, Agnelli G, Corea F, Ageno W, Alberti A, Lanari A, et al. Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study. Stroke. 2008;39(8):2249-56. DOI: https://doi.org/10.1161/STROKEAHA.107.510321
Yaghi S, Henninger N, Giles JA, Leon Guerrero C, Mistry E, Liberman AL, et al. Ischaemic stroke on “anticoagulation” therapy and early recurrence in acute cardioembolic stroke: the IAC study. J Neurol Neurosurg Psychiat. 2021;92:1062-7. DOI: https://doi.org/10.1136/jnnp-2021-326166
Piccini JP, Patel MR, Steffel J, Ferdinand K, Van Gelder IC, Russo AM, et al. OCEANIC-AF Steering Committee and Investigators. Asundexian versus Apixaban in Patients with Atrial Fibrillation. N Engl J Med. 2024;3:875.
Sharma M, Molina CA, Toyoda K, Bereczki D, Bangdiwala SI, Kasner SE, et al. Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATICSSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol. 2024;23:46-59. DOI: https://doi.org/10.1016/S1474-4422(23)00403-9
Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al ; External reviewers. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021;23(10):1612-76. DOI: https://doi.org/10.1093/europace/euab065
Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, et al. 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American heart association/American stroke association. Stroke. 2021;52(7):364-467. DOI: https://doi.org/10.1161/STR.0000000000000375
Jenni R, Oechslin E, Schneider J, AttenhoferJost C, Kaufmann PA. Echocardiographic and pathoanatomical characteristics of isolated left ventricular non-compaction: a step towards classification as a distinct cardiomyopathy. Heart. 2001;86:666–71. DOI: https://doi.org/10.1136/heart.86.6.666
Siontis KC, Zhang X, Eckard A, BhaveN, Schaubel DE, He K,et al. Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. Circulation. 2018;138:1519–29. DOI: https://doi.org/10.1161/CIRCULATIONAHA.118.035418
Klijn CJ, Paciaroni M, Berge E, Korompoki E, Kõrv J, Lal A, et al. Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline. Eur Stroke J. 2019;4(3):198-223. DOI: https://doi.org/10.1177/2396987319841187
Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation. 1991;84(2):527-39. DOI: https://doi.org/10.1161/01.CIR.84.2.527
Yaghi S, Mistry E, Liberman AL, Giles J, Asad SD, Liu A, et al. “anticoagulation” Type and Early Recurrence in Cardioembolic Stroke: The IAC Study. Stroke. 2020;51(9):2724-32. DOI: https://doi.org/10.1161/STROKEAHA.120.028867
Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955–62. DOI: https://doi.org/10.1016/S0140-6736(13)62343-0
Paciaroni M, Bandini F, Agnelli G, Tsivgoulis G, Yaghi S, Furie KL, et al. Hemorrhagic transformation in patients with acute ischemic stroke and atrial fibrillation: time to initiation of oral anticoagulant therapy and outcomes. J Am Heart Assoc. 2018;7:10133. DOI: https://doi.org/10.1161/JAHA.118.010133
Kimura S, Toyoda K, Yoshimura S, Minematsu K, Yasaka M, Paciaroni M, et al. SAMURAI, RELAXED, RAF, RAF-NOAC, CROMIS-2, NOACISP LONGTERM, Erlangen registry and Verona registry investigators. practical "1-2-3-4-day" rule for starting direct oral anticoagulants after ischemic stroke with atrial fibrillation: combined hospital-based cohort study. Stroke. 2022;53(5):1540-9. DOI: https://doi.org/10.1161/STROKEAHA.121.036695
Oldgren J, Åsberg S, Hijazi Z, Wester P, Bertilsson M, Norrving B. National TIMING Collaborators. Early Versus Delayed Non-Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study. Circulation. 2022;146(14):1056-66. DOI: https://doi.org/10.1161/CIRCULATIONAHA.122.060666
Fischer U, Koga M, Strbian D, Branca M, Abend S, Trelle S, et al. ELAN Investigators. Early versus Later “anticoagulation” for Stroke with Atrial Fibrillation. N Engl J Med. 2023;388(26):2411-21. DOI: https://doi.org/10.1056/NEJMoa2303048
Werring DJ, Dehbi HM, Ahmed N, Arram L, Best JG, Balogun M, et al. OPTIMAS investigators. Optimal timing of “anticoagulation” after acute ischaemic stroke with atrial fibrillation (OPTIMAS): a multicentre, blinded-endpoint, phase 4, randomised controlled trial. Lancet. 2024;23:736. DOI: https://doi.org/10.1016/S0140-6736(24)02197-4
Rohner R, Kneihsl M, Goeldlin MB, Hakim A, Branca M, Abend S, et al. ELAN investigators. early versus late initiation of direct oral anticoagulants after ischemic stroke in people with atrial fibrillation and hemorrhagic transformation: prespecified subanalysis of the randomized controlled ELAN Trial. Circulation. 2024;150(1):19-29. DOI: https://doi.org/10.1161/CIRCULATIONAHA.124.069324
Sakusic A, Rabinstein AA, Anisetti B, Mandrekar J, Wijdicks EFM, Freeman WD, et al. Timing of “anticoagulation” resumption and risk of ischemic and hemorrhagic complications in patients with ich and mechanical heart valves. Neurology. 2024;103(4):209664. DOI: https://doi.org/10.1212/WNL.0000000000209664
Grosse GM, Hüsing A, Stang A, Kuklik N, Brinkmann M, Nabavi D, et al. PRODAST Investigators. Early or late initiation of dabigatran versus vitamin-K-antagonists in acute ischemic stroke or TIA: The PRODAST study. Int J Stroke. 2023;18(10):1169-77. DOI: https://doi.org/10.1177/17474930231184366
Goyal M, Menon BK, van Zwam WH, Dippel DW, Mitchell PJ, Demchuk AM, et al. Endovascular thrombectomy after largevesselischaemic stroke: a meta-analysis of individual patientdata from five randomised trials. Lancet. 2016;387:1723-31. DOI: https://doi.org/10.1016/S0140-6736(16)00163-X
Olthuis SGH, Pirson FAV, Pinckaers FME, Hinsenveld WH, Nieboer D, Ceulemans A, et al. Endovascular treatment versusno endovascular treatment after 6-24 h in patients withischaemic stroke and collateral flow on CT angiography (MRCLEAN-LATE) in the Netherlands: a multicentre, open-label, blinded-endpoint, randomised, controlled, phase 3 trial. Lancet. 2023;401:1371-80. DOI: https://doi.org/10.1016/S0140-6736(23)00575-5
Ma H, Che R, Zhang Q, Yu W, Wu L, Zhao W, et al. The optimum”anticoagulation” time after endovascular thrombectomyfor atrial fibrillation-related large vessel occlusion stroke: areal-world study. J Neurol. 2023;270:2084-95. DOI: https://doi.org/10.1007/s00415-022-11515-y
Nishimoto T, Oka F, Okazaki K, Ishihara H. Timing of directoral anticoagulants for hemorrhagic transformation afterendovascular treatment in acute ischemic stroke. J Stroke Cerebro vasc Dis. 2022;31:106507. DOI: https://doi.org/10.1016/j.jstrokecerebrovasdis.2022.106507
Downloads
Published
How to Cite
Issue
Section
